How to select the right cost-effectiveness model? A systematic review and stepwise approach for selecting a transferable health economic evaluation model for rheumatoid arthritis

PharmacoEconomics

Volumn 32, Issue 5, 2014, Pages 429-442

  Van Haalen, H G M ^a,b   Severens, J L ^a   Tran Duy, A ^c,d   Boonen, A ^c  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ASTRAZENECA   (United Kingdom)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ANTIRHEUMATIC AGENT;

CLINICAL DECISION MAKING; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; ECONOMIC EVALUATION; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; COST BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT SYSTEM; ECONOMICS; HEALTH CARE COST; NETHERLANDS; STATISTICAL MODEL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT TECHNIQUES; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; NETHERLANDS;

EID: 84902311231     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0139-9     Document Type: Review

References (68)

1. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess. 2004;8(49):iii,iv, 1-192.
2. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12(4):409-18.
3. Goeree R, He J, O'Reilly D, Tarride JE, Xie F, Lim M, et al. Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. Clinicoecon Outcomes Res. 2011;3:89-104.
4. Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics. 2004;22(13):857-76. (Pubitemid 39273956)
5. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130-6. (Pubitemid 40488741)
6. Eriksson JK, Neovius M, Ernestam S, Lindblad S, Simard JF, Askling J. Incidence of rheumatoid arthritis in Sweden-a nationwide population-based assessment of incidence, its determinants, and treatment penetration. Arthritis Care Res (Hoboken). 2013;65:870-8.
7. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2008;14(4):234-54.
8. Fautrel B. Economic benefits of optimizing anchor therapy for rheumatoid arthritis. Rheumatology (Oxford). 2012 Jun;51 Suppl 4:iv21-6.
9. Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol. 2003;30(4):891-6. (Pubitemid 36402796)
10. Bansback N, Ara R, Karnon J, Anis A. Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health states. Pharmacoeconomics. 2008;26(5):395-408. (Pubitemid 351572052)
11. Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs. 2005;65(4):473-96. (Pubitemid 40469553)
12. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force - 6. Value Health. 2012;15(6):835-42.
13. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355-71.
14. Cimmino MA, Leardini G, Salaffi F, Intorcia M, Bellatreccia A, Dupont D, et al. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach. Clin Exp Rheumatol. 2011;29(4):633-41.
15. Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis. 2005;64(7):995-1002. (Pubitemid 40909512)
16. Beresniak A, Ariza-Ariza R, Garcia-Llorente JF, Ramirez-Arellano A, Dupont D. Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain. Int J Inflamm. 2011;2011:727634.
17. Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15(14):1-278.
18. Barton P. Development of the Birmingham Rheumatoid Arthritis Model: past, present and future plans. Rheumatology (Oxford). 2011;50 Suppl 4:iv32-8.
19. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess. 2004;8(11):iii, 1-91.
20. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006;10(42):iii, iv, xi-xiii, 1-229.
21. Clark W, Jobanputra P, Barton P, Burls A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol Assess. 2004;8(18):iii, iv, ix-x, 1-105.
22. Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2002;6(21):1-110.
23. Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford). 2004;43(1):62-72. (Pubitemid 38088370)
24. Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford). 2007;46(8):1345-54. (Pubitemid 47244512)
25. Chiou CF, Choi J, Reyes CM. Cost-effectiveness analysis of biological treatments for rheumatoid arthritis. Expert Rev Pharmacoecon Outcomes Res. 2004;4(3):307-15. (Pubitemid 38745087)
26. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol. 2002;29(6):1156-65. (Pubitemid 34601947)
27. Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol. 2009;36(1):16-26.
28. Diamantopoulos A, Benucci M, Capri S, Berger W, Wintfeld N, Giuliani G, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ. 2012;15(3):576-85.
29. Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, et al. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med. 2009;151(9):612-21.
30. Hallinen TA, Soini EJ, Eklund K, Puolakka K. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology (Oxford). 2010;49(4):767-77.
31. Kielhorn A, Porter D, Diamantopoulos A, Lewis G. UK cost- utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Curr Med Res Opin. 2008;24(9):2639-50.
32. Lekander I, Borgstrom F, Svarvar P, Ljung T, Carli C, van Vollenhoven RF. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. Int J Technol Assess Health Care. 2010;26(1):54-61.
33. Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2310-9.
34. Kobelt G, Lindgren P, Young A. Modelling the costs and effects of leflunomide in rheumatoid arthritis. Eur J Health Econ. 2002;3(3):180-7. (Pubitemid 36402001)
35. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford). 2003;42(2):326-35. (Pubitemid 36305621)
36. Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford). 2005;44(9):1169-75. (Pubitemid 41236026)
37. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis. 2005;64(8):1174-9. (Pubitemid 41113352)
38. Kobelt G, Lekander I, Lang A, Raffeiner B, Botsios C, Geborek P. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care. 2011;27(3):193-200.
39. Lindgren P, Geborek P, Kobelt G. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from southern Sweden. Int J Technol Assess Health Care. 2009;25(2):181-9.
40. Kobelt G, Lindgren P, Geborek P. Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data. Scand J Rheumatol. 2009;38(6):409-18.
41. Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum. 2002;47(6):655-61. (Pubitemid 35461320)
42. Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, et al. Not all "quality-adjusted life years" are equal. J Clin Epidemiol. 2007;60(6):616-24. (Pubitemid 46711077)
43. Merkesdal S, Kirchhoff T, Wolka D, Ladinek G, Kielhorn A, Rubbert-Roth A. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept- failure. Eur J Health Econ. 2010;11(1):95-104.
44. Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, et al. Cost utility of tumour necrosis factor-alpha inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model. Pharmacoeconomics. 2012;30(7):575-93.
45. Puolakka K, Blafield H, Kauppi M, Luosujarvi R, Peltomaa R, Leikola-Pelho T, et al. Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland. Open Rheumatol J. 2012;6:38-43.
46. Russell A, Beresniak A, Bessette L, Haraoui B, Rahman P, Thorne C, et al. Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin Rheumatol. 2009;28(4):403-12.
47. Saraux A, Gossec L, Goupille P, Bregman B, Boccard E, Dupont D, et al. Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. Rheumatology (Oxford). 2010;49(4):733-40.
48. Schadlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, et al. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency. Pharmacoeconomics. 2005;23(4):395-420. (Pubitemid 40677056)
49. Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ. 2012;15(2):340-51.
50. Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics. 2006;24(12):1221-32. (Pubitemid 44901677)
51. Suka M, Yoshida K. Cost effectiveness of leflunomide in the treatment of rheumatoid arthritis in Japan. Expert Rev Pharmacoecon Outcomes Res. 2004;4(6):617-22. (Pubitemid 39591896)
52. Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, et al. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol. 2006;16(2):77-84.
53. Tosh JC, Wailoo AJ, Scott DL, Deighton CM. Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis. J Rheumatol. 2011;38(8):1593-600.
54. Tosh J, Brennan A, Wailoo A, Bansback N. The Sheffield Rheumatoid Arthritis Health Economic Model. Rheumatology (Oxford). 2011;50 Suppl 4:iv26-31.
55. Yuan Y, Trivedi D, Maclean R, Rosenblatt L. Indirect coste-ffectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. J Med Econ. 2010;13(1):33-41.
56. Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. J Rheumatol. 2008;35(9):1745-53.
57. Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford). 2008;47(4):535-41.
58. Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum. 2008;58(4):939-46. (Pubitemid 351563994)
59. Welsing PM, Severens JL, Hartman M, van Gestel AM, van Riel PL, Laan RF. The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis. Pharmacoeconomics. 2006;24(10):1011-20. (Pubitemid 44497472)
60. Welsing PM, Severens JL, Hartman M, van Riel PL, Laan RF. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum. 2004;51(6):964-73. (Pubitemid 39648190)
61. Schipper LG, Kievit W, den Broeder AA, van der Laar MA, Adang EM, Fransen J, et al. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford). 2011;50(7):1320-30.
62. Barbieri M, Wong JB, Drummond M. The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics. 2005;23(6):607-18. (Pubitemid 40994128)
63. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med. 2002;113(5):400-8. (Pubitemid 35223612)
64. Beaudet A, Palmer JL, Timlin L, Wilson B, Bruhn D, Boye KS, et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ. 2011;14(3):357-66.
65. Hiligsmann M, Cooper C, Arden N, Boers M, Branco JC, Luisa Brandi M, et al. Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2013;43(3):303-13.
66. The Royal Society. Science as an open enterprise: open data for open science; 2012. http://royalsociety.org/uploadedFiles/Royal-Society-Content/ policy/projects/sape/2012-06-20-SAOE.pdf.
67. Blum S, Vardi M, Brown JB, Russell A, Milman U, Shapira C, et al. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics. 2010;11(5):675-84.
68. Toumi M, Antonanzas F, Hakkaart L, Lam RW, McCrone P, Persson U, et al. Comprehensive discrete event simulation model for the evaluation of health care technologies in depression. Value Health. 2012;15(7):A282.